Long-term outcome after liver transplantation in children

Pediatric Transplantation

Volumn 6, Issue 1, 2002, Pages 30-36

  Bucuvalas, John C ^a,b   Ryckman, Frederick C ^a  

^a CINCINNATI CHILDREN S HOSPITAL RESEARCH FOUNDATION   (United States)

^b CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

Author keywords

Outcome; Pediatric liver transplantation; Quality of life

Indexed keywords

CALCINEURIN INHIBITOR; CYCLOSPORIN;

ALLOGRAFT; CANCER; CARDIOVASCULAR DISEASE; CONFERENCE PAPER; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FAILURE; LIPID BLOOD LEVEL; LIVER TRANSPLANTATION; OSTEOPOROSIS; QUALITY OF LIFE; TREATMENT OUTCOME; UNITED STATES;

ADAPTATION, PHYSIOLOGICAL; ADOLESCENT; CHILD; CHILD DEVELOPMENT; CHILD, PRESCHOOL; COST-BENEFIT ANALYSIS; FEMALE; FOLLOW-UP STUDIES; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; LIVER TRANSPLANTATION; LONG-TERM CARE; MALE; QUALITY OF LIFE; SURVIVAL RATE; TIME FACTORS; TREATMENT OUTCOME;

EID: 0036209020     PISSN: 13973142     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1399-3046.2002.1r058.x     Document Type: Conference Paper

References (61)

1. Bone loss after orthotopic liver transplantation
2. Renal outcomes in pediatric liver transplantation
3. Renal function in pediatric liver transplant patients
4. Ten years of liver transplantation: An evolving understanding of late graft loss
5. Orthotopic liver transplantation for hepatitis C
6. Long-term survival after liver transplantation
7. Randomised trial comparing tacrolimus (FK506) and cyclosporin in prevention of liver allograft rejection
8. A comparison of tacrolimus, (FK 506) and cyclosporine for immunosuppression in liver transplantation
9. The clinical impact of nephrotoxicity n liver transplantation
10. Nephrotoxic effects of primary immunosuppression with FK-506 and cyclosporine regimens after liver transplantation
11. Nephrotoxicity following orthotopic liver transplantation. A comparison between cyclosporine and FK506
12. Renal function in patients receiving long-term cyclosporine therapy
13. Cyclosporin in therapeutic doses increases renal allograft vascular resistance
14. Transforming growth factor-beta 1 hyperexpression in African American endstage renal disease patients
15. Intragraft TGF-beta 1 mRNA, a correlate of interstitial fibrosis and chronic allograft nephropathy
16. Glomerular filtration rate after liver transplantation with a low-dose cyclosporin protocol
17. Chronic renal failure following liver transplantation: A retrospective analysis
18. Endstage renal disease following orthotopic liver transplantation utilizing calcineurin inhibitors
19. Bone metabolism in orthotopic liver transplantation: A prospective study
20. Effect of orthtopic liver transplantation on bone mineral content and serum vitamin D metabolites in infants and children with chronic cholestasis
21. Atherosclerosis, a nutritional disease of childhood
22. Precursors of cardiovascular risk in young adults from a biracial (black-white) population: The Bogalusa Heart Study
23. Post-transplant malignancy: The role of immunosuppression
24. Occurrence of cancers in immunosuppressed organ transplant recipients
25. Cancers in renal transplant recipients
26. CD4 lymphocytopenia as a risk factor for skin cancers in renal transplant recipients
27. Skin cancer in heart transplant recipients. Frequency and risk factor analysis
28. Skin cancer in heart transplant recipients, risk factor analysis and relevance of immunosuppressive therapy
29. Early signs and risk factors for the increased incidence of Epstein-Barr virus-related posttransplant lymphoproliferative diseases in pediatric liver transplant recipients treated with tacrolimus
30. Rational management of posttransplant lymphoproliferative disorder in pediatric recipients
31. Prevention and preemptive therapy of postransplant lymphoproliferative disease in pediatric liver recipients
32. Health-related quality of life in long-term survivors of pediatric liver transplantation
33. Quality of life in children undergoing liver transplants overseas or in Japan
34. Changes in life-style after liver transplantation
35. Parental psychosocial outcomes in pediatric liver and/or intestinal transplantation. Pretransplantation and the early postoperative period
36. Psychosocial issues in pediatric organ transplantation: The parents' perspective
37. Psychological and social adjustment after pediatric liver transplantation as a function of age at surgery and of time elapses since transplantation
38. Children and families can achieve normal psychological adjustment and a good quality of life following pediatric liver transplantation: A long-term study
39. Factors affecting growth after pediatric liver transplantation
40. Growth in children following liver transplantation
41. Linear growth after pediatric liver transplantation
42. Neurodevelopmental outcome of young children with extrahepatic biliary atresia 1 year after liver transplantation
43. Non-adherence in pediatric liver transplant recipients - An assessment of risk factors and natural history
44. Care of the pediatric solid organ transplant recipient. The primary care perspective
45. Transplant allograft loss in the adolescent patient
46. Weighing risks and taking chances: Adolescents' experiences of the regimen after renal transplantation
47. Timing, significance, and prognosis of late acute liver allograft rejection
48. Cost-effectiveness of ursodeoxycholic acid therapy in primary biliary cirrhosis
49. Predictors of cost of liver transplantation in children: A single center study
50. The impact of surgical complications after liver transplantation on resource utilization
51. Predictors of the cost of liver transplantation
52. Evolving trends in liver transplantation, an outcome and charge analysis
53. Biliary complications of reduced-organ liver transplantation
54. Costs and outcomes of liver transplantation in adults
55. The influence of clinical variables on hospital costs after orthotopic liver
56. Immunosuppression with tacrolimus (FK 506) and cyclosporin A for preventing graft rejection after liver transplantation. Retrospective evaluation of medical costs based on the FG-0157 Study in 224 patients
57. Economic evaluation of Neoral versus Sandimmune maintenance therapy for de novo liver transplant patients: Results from an International Randomized Controlled Trial
58. A pharmacoeconomic analysis of Neoral without intravenous cyclosporine in liver transplantation in Canada
59. The impact of immunosuppressive regimens on the cost of liver transplantation - Results from the U.S. FK506 multicenter trial
60. Enhanced oral cyclosporine absorption with water-soluble vitamin E early after liver transplantation